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ABSTRACT 
Introduction: Breast cancer stem cells (BCSCs) are identified as side populations in 
breast cancer cells owing stem cell properties and tumorigenic characteristics. Previous 
studies revealed that breast cancer chemotherapy led to BCSC enrichment which 
contributed to therapy resistance. Our recent in vivo study using Next Generation 
Sequencing has demonstrated that PCNA - the proliferative gene - and BIRC5 – the anti-
apoptosis gene – were under-expressed in human breast tumors after neoadjuvant 
chemotherapy. This study aimed to verify the role of PCNA and BIRC5 expression in 
doxorubicin-treated human BCSCs in vitro and its association with cell viability. Method: 
Human BCSCs (ALDH+) were treated with 0.25 uM of doxorubicin for 2, 4, 6, 8, 10, 12, 14 
days respectively. Cell viability was measured using trypan blue exclusion assay and the 
expressions of PCNA and BIRC4 mRNA were determined using qRT-PCR. Results: This 
study demonstrated that the viability of ALDH+ BCSCs decreased after 2 days and 
increased again after 8 days of doxorubicin treatment, indicating the decrease of doxorubicin 
sensitivity. Interestingly, PCNA and BIRC5 genes were modulated in line with the 
modulation of cell viability during doxorubicin treatment of human BCSCs. Conclusion: In 
conclusion, we suggest that the PCNA and BIRC5 expressions play an important role on the 
BCSCs viability which associated with the sensitivity of doxorubicin treatment. 
 
Keywords: human breast cancer stem cells, cell viability, PCNA, BIRC5, doxorubicin 
 
 
Breast cancer is the most death-causing cancer 
among women all over the world due to therapy 
resistance and disease recurrence. Nowadays, 
neoadjuvant therapy is established for larger 
primary and locally advanced breast cancer as a 
preoperative approach. The advantages of 
neoadjuvant therapy is to downstaging the tumor, 
reducing the extent surgery and also evaluating 
the efficacy of the drugs that will be 
administered.(1) Yet, classic breast cancer 
therapy has not considered the presence of  side 
populations, known as breast cancer stem cells 
(BCSCs), that are characterized by self-renewal, 
differentiation, and tumorigenic capabilities, 
similar to normal stem cells.(2) 
Current treatments for breast cancer 
frequently fail to eradicate tumor since they are 
inable to effectively target BCSC populations. 
BCSCs have been proved to exhibit significant 
resistance to conventional chemotherapy. 
Furthermore, breast cancer chemotherapy may 
lead to BCSC enrichment which contributed to 
therapy resistance. It has been demonstrated that 
BCSC markers (CD44+/CD24-) were expressed 
abundantly after neoadjuvant chemotherapy of 
primary breast cancer patients.(3) Some previous 
studies have also reported that BCSCs are 
responsible for therapy resistance, recurrence and 
metastasis in breast cancer.(4),(5),(6) The 
presence of BCSC populations has been correlated 
with poor prognosis in breast cancer patients.(7) 
 
Very recently, we have applied Next 
Generation Sequencing to assess the alteration of 
p53-pathway gene expressions in breast cancer 
cells from patients underwent neoadjuvant 
chemotherapy. We found that seven gene 
expressions in p53-pathway were significantly 
down-regulated after neoadjuvant chemotherapy 
of breast cancer patients, namely ATM, BID, 
BIRC5, CASP8, CASP9, CDK1 and PCNA.(8) 
Proliferating cell nuclear antigen (PCNA) is 
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known as a molecular marker for cell 
proliferation, thereby it has an important role in 
replication. The function of PCNA is 
indispensable for the maintenance of genomic 
integrity and propagation in actively growing 
cells.(9) BIRC5 or survivin is a member of the 
inhibitor of apoptosis (IAP) protein family that 
suppresses caspase-9 activity leading to apoptosis 
inhibition. This protein is highly expressed in 
most cancers and is associated with a poor clinical 
outcome. (10) Our previous study has 
demonstrated that BIRC5 was highly expressed 
in BCSCs after oxidative stress induction and led 
to high cell survival.(11)  
 
The present study aimed to verify the role of 
PCNA and BIRC5 expressions on the sensitivity 
of human BCSC against chemotherapy. We 
analysed the decrease of BCSC sensitivity against 
doxorubicin by determining cell viability in 
association with PCNA and BIRC5 expressions in 
human BCSCs (ALDH+) after repeated exposure 
to doxorubicin treatment. The result of this study 
is consistent to our previous next generation 
sequencing analysis, suggesting that PCNA and 
BIRC5 could be used as markers for determining 
chemotherapy sensitivity, particularly in BCSCs.      
 
MATERIALS AND METHODS 
Cell culture 
Human BCSCs (ALDH+) were grown in 
serum free DMEM F12 medium with 1% 
penicillin/streptomycin and 1% amphotericin B 
and incubated in 5% CO2 at 37˚C. 
 
Cytotoxic Assay 
MTS assay was performed to determine 
cytotoxicity of human BCSCs. About 1x103 human 
BCSCs (ALDH+) were plated triplicate in each 
well of 96-well plate and grown in non-serum 
DMEM/F12 medium supplemented with 1% 
penicillin/streptomycin and 1% amphotericin at 
370C and 5% CO2. After 24-incubation, cells were 
treated with various concentrations of 
doxorubicin (0.1, 0.5, 1, 5, 10 and 20 µM) for 24 
hours. As controls, cells were grown without 
doxorubicin under standard conditions for 24 
hours. Afterwards, medium was replaced with 
100 µl fresh DMEM/F12 medium containing 20 µl 
MTS/PMS (20:1) and incubated for 1 hour. After 
the brown colour has appeared, the absorbance 
was read at 490 nm using microplate reader 
(Varioskan®, Thermo Fisher Scientific USA). The 
absorbances of doxorubicin-treated cells were 
normalized to that of control cells to calculate the 
percentage of cell viability.  
 
Doxorubicin treatment 
Approximately 1x105 cells were plated each 
well in12 well-plate and incubated overnight. 
Afterwards, medium was replaced with fresh 
DMEM/F12 medium containing doxorubicin of 
0.25 µM for 2, 4, 6, 8, 10, 12, and 14 days 
respectively. As controls, cells were grown in 
DMEM/F12 without doxorubicin for 2, 4, 6, 8, 10, 
12, and 14 days respectively. After incubation, 
cells were harvested and counted using trypan 
blue exclusion assay and automated cell counter 
(Luna®, Logos Biosystems Korea). The number of 
viable doxorubicin-treated cells was normalized to 
that of the respective control cells to calculate the 
percentage of cell viability. Total RNA and 
isolated from the cells using Tripure® isolation 
reagent kit (Roche) according to the 
manufacturer’s instructions. 
 
Quantitative RT-PCR 
The concentration of total RNA was measured 
using spektrofluorometer (Varioskan, Thermo 
Fisher Scientific USA). One-step quantitative RT-
PCR was carried out using ECO48® real time 
qPCR system (PCRmax UK). The RT PCR was 
performed in 20 µL volume with 100 ng total 
RNA. The primer sequence for quantitative RT-
PCR are listed in table 1. PCR cycles are 45 C 
incubation for 5 minutes initially, followed by a 3-
minute incubation at 95 C, then 40 cycles of 
95 C for 5 seconds, 55 C for 30 seconds, 72 C for 
30 seconds, and  melting curve incubation. 
Relative expression was relatively calculated 
using Livak formula(12) with 18S rRNA gene as a 
reference gene and normalized to its respective 
control. 
 
RESULTS 
Cytotoxic Assay  
Cytotoxicity of doxorubicin treatment on 
human BCSCs (ALDH+) was determined using 
MTS assay. The 50% cytotoxicity concentration 
(CC50) was calculated using cytotoxicity curve 
generated by logarithmic regression equation (y= 
-9.572ln(x) + 62.291). As shown in Figure 1, CC50 
value of doxorubicin on human BCSCs was 3.63 
µM. Based on this data, we used doxorubicin 
concentration lower than CC50 for all 
experiments. 
 
Cell Viability 
Percentage of cell viability was determined by 
comparing the number of viable doxorubicin-
treated cells with that of control cells. Figure 2 
demonstrates that BCSC viability after 2-day 
doxorubicin treatment decreased (66%), however 
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started to increase on day 8 (81%) until reached 
92% viability on day 14. 
 
Relative mRNA expression of PCNA and 
BIRC5 after doxorubicin treatment 
To analyze the role of PCNA and BIRC5 on 
the sensitivity of BCSCs against doxorubicin, we 
examined the relative expression of PCNA and 
BIRC5 mRNA following 2-, 6-, 10-, and 14-day 
doxorubicin treatment. Compared to each 
respective controls, PCNA mRNA expression was 
significantly decreased after 2-day treatment 
(0.787-times; p=0.040), but slightly increased on 
day 10 (1.337-times; p=0.236) and day 14 day of 
treatment (1.437-times; p= 0.169) (Fig. 3). PCNA 
relative expressions in BCSCs treated with 
doxorubicin for 10 and 14 day  was significantly 
higher compared to that with 2-day treatment 
(p=0.016 and p=0.011 respectively, One-way 
ANOVA test). Relative expression of BIRC5 
mRNA in human BCSCs treated with doxorubicin 
was also modulated in a similar manner to PCNA 
expression. It was decreased after 2-day 
treatment of doxorubicin (0.846; p=0.089), but 
started to increase on day 10 (1.257; p= 0.140) and 
day 14 of treatment (1.530; p=0.094) compared to 
each respective controls (Fig. 4). Although there 
were no significant differences compared to 
controls, the increase of BIRC5 relative 
expression  in BCSCs after 10- and 14-day 
doxorubicin treatment was significantly higher 
compared to 2-day treatment (p=0.027 and 
p=0.001, One-way ANOVA test).
 
Table and Figures 
 
Table 1. Primer sequence of PCNA, Survivin and 18S rRNA 
No. Gene Primer Sequence  Poduct 
1. PCNA F: 5’- CTT CCC TTA CGC AAG TCT CAG -3’ 
R: 5’- TTG AGT GCC TCC AAC ACC TT -3’ 
189 bp 
2. Survivin F: 5’- AGG ACC ACC GCA TCT CTA CA -3’ 
R: 5’- GTT CCT CTA TGG GGT CGT CA -3’ 
186 bp 
3. 18S rRNA F: 5’- AAA CGG CTA CCA CAT CCA AG -3’ 
R: 5’- CCT CCA ATG GAT CCT CGT TA -3’ 
155 bp 
 
Figure 1. Cytotoxic assay of doxorubicin-treated BCSCs. MTS assay was performed to determined 
cytotoxicity of human BCSCs. About 1x103 human BCSCs (ALDH+) were plated triplicate in each well of 
96-well plate and grown in non-serum DMEM/F12 medium supplemented with 1% penicillin/streptomycin 
and 1% amphotericin at 370C and 5% CO2. After 24-incubation, cells were treated with various 
concentrations of doxorubicin (0.1, 0.5, 1, 5, 10 and 20 µM) for 24 hours. As controls, cells were grown without 
doxorubicin under standard conditions for 24   
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Figure 2. Viability of doxorubicin-treated BCSCs. Approximately 1x105 cells were plated in each well 
of 12 well-plate and incubated overnight. Afterwards, medium was replaced with fresh DMEM/F12 
medium containing doxorubicin of 0.25 µM for 2, 4, 6, 8, 10, 12, and 14 days respectively. As controls, cells 
were grown in DMEM/F12 without doxorubicin for 2, 4, 6, 8, 10, 12, and 14 days respectively. After 
incubation, cells were harvested and counted using trypan blue exclusion assay and automated cell counter 
(Luna). The number of viable doxorubicin-treated cells was normalized to that of the respective control 
cells to calculate the percentage of cell viability. Significant differences are considered at *p<0.05 (One-
way ANOVA test) compared to cell viability after 2-day doxorubicin treatment. Significant differences 
compared to each respective controls are considered at ##p<0.01 and #p<0.05 (Student’s t-test). 
 
Figure 3. Relative expression of PCNA mRNA in doxorubicin-treated BCSCs. Human BCSCs 
(ALDH+) were treated with doxorubicin 0.25 µM and incubated for 2, 6, 10, and 14 days respectively. As 
controls, cells were grown without doxorubicin for 2, 6, 10, and 14 days respectively. After incubation, cells 
were harvested for total RNA isolation. Quantitative RT-PCR was performed using 100 ng total RNA to 
determine PCNA mRNA relative expression levels in human BCSCs, as described under Materials and 
Methods. The expression was relatively calculated using Livak formula with 18S rRNA gene as a reference 
gene and normalized to its respective control. All values are means ± SE, n = 6. Significant differences are 
considered at *p<0.05 (One-way ANOVA test) compared to 2-day doxorubicin treatment. Significant 
differences compared to each respective control are considered at #p<0.05 (t test). 
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Figure 4. Relative expression of BIRC5 mRNA in doxorubicin-treated BCSCs. Human BCSCs 
(ALDH+) were treated with doxorubicin 0.25 µM and incubated for 2, 6, 10, and 14 days respectively. As 
controls, cells were grown without doxorubicin for 2, 6, 10, and 14 days respectively. After incubation, cells 
were harvested for total RNA isolation. Quantitative RT-PCR was performed using 100 ng total RNA to 
determine BIRC5 mRNA relative expression levels in human BCSCs, as described under Materials and 
Methods. The expression was relatively calculated using Livak formula with 18S rRNA gene as a reference 
gene and normalized to its respective control. All values are means ± SE, n = 6. Significant differences are 
considered at **p<0.01 and *p<0.05,(One-way ANOVA test) compared to 2-day doxorubicin treatment.
DISCUSSION 
Breast cancer stem cells could be identified 
based on several surface antigen markers such as 
CD44 CD24  or ALDH1+.(13),(14) High 
expression of ALDH1 is correlated with poor 
prognosis. Some studies reported that high 
number of BCSC was shown to be capable of 
tumorigenesis, metastasis, and drug 
resistance.(6),(15) This study was performed to 
analyse the role of PCNA and BIRC5 gene 
expression in response to repeated exposure of 
doxorubicin especially in ALDH1+ breast cancer 
stem cells.  
Result of cell viability percentage shows the 
decreasing of the BCSC viability in the early of 
doxorubicin treatment (until day 6), suggesting 
that BCSCs were still sensitive to doxorubicin 
therapy. However, this study shows that the 
sensitivity of BCSC against doxorubicin began to 
decrease after 8-day doxorubicin treatment and 
reached 92% viability on day 14.  
The present study indicated that the 
expressions of PCNA and BIRC5 were modulated 
in line with the modulation of human BCSC 
viability during doxorubicin treatment for 14 
days. Both genes were expressed lower than 
control on day 2 and 6, but significantly higher on 
day 10 and 14 of doxorubicin treatment. 
Therefore, we confirm that PCNA and BIRC5 
gene expressions involved in the sensitivity of 
BCSC against doxorubicin by regulating the cell 
viability, which is consistent to our previous study 
using next generation sequencing.8  
PCNA is a responsible factor for DNA 
replication and repair and contribute to cell 
proliferation. Cell growth/proliferation is a 
requirement for cancer progression, so PCNA 
plays important role in cancer progression at both 
primary and metastatic sites. PCNA 
phosphorylation is stimulated by epidermal 
growth factor (EGF). When EGF binds the 
receptor (EGFR), it will lead the PCNA  
phosphorylation on tyrosine residue 211 (pY211). 
The phosphorylated-PCNA (pY211-PCNA) was 
found frequently in human breast cancer, and the 
levels of pY211-PCNA were correlated with poor 
overall survival.(16) On the other hand, PCNA 
also acts as an antiapoptotic activity through 
interaction with proteins of the Gadd45 family 
(Gadd45, MyD118, and CR6), which are 
contributed in growth control, apoptosis, and 
DNA repair. PCNA interaction in these protein 
will inhibit their activities.(17) PCNA has also 
been widely used as a tumor marker, and its 
expression is correlated poor prognosis.(18)  
BIRC5 (Survivin) is an inhibitor of apoptosis 
protein and is expressed in a lot of malignancies, 
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including breast cancer.(19) Overexpression of 
BIRC5 gene in cancer may overcome cell cycle 
checkpoints to facilitate aberrant progression of 
transformed cells through mitosis, suggesting the 
involvement of this gene in tumor aggressiveness 
and therapy resistance.(20) Its expression levels 
correlate with more aggressive disease and poor 
clinical outcome. Khan et al reported higher 
expression of BIRC5 as a critical factor for 
radioresistance in head and neck squamous cell 
carcinoma (HNSCC) cell lines.(21) A study 
reported that reducing the mRNA levels of BIRC5 
to approximately 40%, results in a concomitant 
reduction of OCT4 and NANOG mRNA. It 
suggesting that BIRC5 plays a role in 
pluripotency.(22) 
PCNA and BIRC5 are genes that  involved in 
p53 signalling pathway. The p53-binding sites are 
present in PCNA gene promoter.(23) Induction of 
PCNA transcription is regulated by p53 protein in 
response to DNA damage (radiation or other 
stresses) to stimulate DNA repair. Low and 
moderate levels of p53 positively stimulate 
transcription of PCNA, while high levels of p53 
inhibit PCNA expression.(24)  BIRC5 is a target 
of p53 protein for its action and downregulation. 
P53 protein may induce apoptosis by antagonizing 
the anti-apoptotic activity of BIRC5. The 
promoter of BIRC5 gene has a p53 binding 
element, thereby it may give the possibility of p53 
binding to BIRC5 promoter either alone or in 
combination with other protein to repress BIRC5 
expression.(25) Based on our results, we suggest 
that BCSCs modulated PCNA and BIRC5 gene 
expressions that regulate cell viability via 
proliferation and anti-apoptosis mechanism in 
response to prolonged exposure to doxorubicin .  
In the presen study, we conclude that the 
PCNA and BIRC5 expressions play an important 
role on BCSCs viability which associated with the 
sensitivity of doxorubicin treatment. Hence, 
PCNA and BIRC5 expressions should be 
considered as markers for determining 
chemotherapy response and sensitivity in 
particular to breast cancer stem cells.       
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